Page last updated: 2024-11-04

nitrofurazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nitrofurazone: A topical anti-infective agent effective against gram-negative and gram-positive bacteria. It is used for superficial WOUNDS AND INJURIES and skin infections. Nitrofurazone has also been administered orally in the treatment of TRYPANOSOMIASIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nitrofurazone : A semicarbazone resulting from the formal condensation of semicarbazide with 5-nitrofuraldehyde. A broad spectrum antibacterial drug, although with little activity against Pseudomonas species, it is used as a local application for burns, ulcers, wounds and skin infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5447130
CHEMBL ID869
CHEBI ID44368
SCHEMBL ID25416
SCHEMBL ID25417
MeSH IDM0014896
PubMed CID1839
CHEMBL ID1603968

Synonyms (290)

Synonym
MLS002153843
smr000059012
AB00373885-04
BRD-K79092138-001-05-2
nsc1602
component of furacort
chemofuran
u-6421
biofuracina
furaldon
furazol w
actin-n
coxistat
furesol
hydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene]-
furazone
5-nitro-2-furfuraldehyde semicarbazone
dermofural
furazyme
furaseptyl
NFS ,
furacort
nci-c56064
furatsilin
nf-7
amifur
component of furadex
nsc-2100
ibiofural
furfurin
5-nitro-2-furfural semicarbazone
furacilin
5-nitrofurazone
cocafurin
furagent
mammex
5-nitrofuraldehyde semicarbazide
nitrofuraldehyde semicarbazone
component of furea
hemofuran
2-furancarboxaldehyde, semicarbazone
monofuracin
nifuzon
monafuracis
furacin
nitrofurazan
furacine
vadrocid
eldezol
alfucin
aldomycin
nitrofurol
nsc-1602
furacoccid
flavazone
6-nitrofuraldehyde semicarbazide
spray-foral
dynazone
1-(5-nitro-2-furfurylidene)semicarbazide
furaderm
yatrocin
otofural
5-nitrofurfural semicarbazone
spray-dermis
sanfuran
veterinary nitrofurazone
nitrozone
chixin
fedacin
usaf ea-4
2-[(5-nitro-2-furanyl)methylene]hydrazinecarboxamide
becafurazone
furazina
furalone
(5-nitro-2-furfurylideneamino)urea
nifurid
furosem
furan-ofteno
wln: t5oj bnw e1unmvz
nfz ,
furaziline
furametral
nsc2100
vabrocid
babrocid
furaplast
nitrofuran (bactericide)
fuvacillin
biofurea
furaskin
fracine
5-nitrofuran-2-aldehyde semicarbazone
monafuracin
nifucin
furacin-hc
nefco
nitrofurane
furazin
mastofuran
5-nitro-2-furancarboxaldehyde semicarbazone
nitrofural
(5-nitro-2-furfurylidenamino)urea
otofuran
eldezol f-6
furacin-e
furacinetten
furacycline
furacillin
BSPBIO_002075
5-nitrofuran-2-carbaldehyde semicarbazone
PRESTWICK2_000492
BPBIO1_000423
PRESTWICK_806
PRESTWICK3_000492
5-nitro-2-furaldehyde, semicarbazone
[(e)-(5-nitro-2-furyl)methyleneamino]urea
SPECTRUM5_001160
BSPBIO_000383
NCGC00090686-01
AB00373885
semikarbazon 5-nitrofurfuralu [polish]
nitrofural [inn]
rivafurazon
2-furancarboxaldehyde, 5-nitro-, semicarbazone
brn 0086403
2-furaldehyde, 5-nitro-, semicarbazone
nitrofurazonum
einecs 200-443-1
ccris 1195
nsc 1602
2((5-nitro-2-furanyl)methylene)hydrazinecarboxamide
nsc 2100
acutol
furacilinum
hydrazinecarboxamide, 2-((5-nitro-2-furanyl)methylene)-
dyanazone
5-nitro-2-furfurylidene semicarbazone
hsdb 3136
rivopon-5
2-furaldehyde, 5-nitro-, semicarbazole
nitrofuralum [inn-latin]
ai3-17333
2-[(5-nitro-2-furanyl)methylene]-hydrazinecarboxamide
59-87-0
C08042
5-nitro-2-furaldehyde semicarbazone
nitrofurazone
DB00336
D00862
furacin (tn)
nitrofural (inn)
nitrofurazone (usp)
IDI1_000778
NCGC00090686-02
NCGC00090686-03
NCGC00090686-04
SPECTRUM1500434
NCGC00090686-05
NCGC00090686-06
5-nitro-2-furaldehyde semicarbazone, >=97.0% (hplc)
HMS2091J04
AC-10331
AKOS000304771
CHEMBL869
HMS502G20
2-[(5-nitro-2-furyl)methylene]hydrazinecarboxamide
[(e)-(5-nitrofuran-2-yl)methylideneamino]urea
N0200
HMS1920B04
HMS1569D05
NCGC00090686-07
NCGC00090686-08
STK741625
(2e)-2-[(5-nitrofuran-2-yl)methylidene]hydrazinecarboxamide
HMS2096D05
semikarbazon 5-nitrofurfuralu
x8xi70b5z6 ,
fura-septin
nitrofurazone [usp:inn:ban]
unii-x8xi70b5z6
dtxcid30809629
tox21_400035
dtxsid5020944 ,
NCGC00260533-01
tox21_202988
pharmakon1600-01500434
nsc-757244
nsc757244
tox21_110997
furalcyn
dymazone
nitrofuralum
CCG-39642
bdbm50420350
112574-44-4
hydrazinecarboxamide, 2-[(5-nitro-2-furanyl)methylene]-, (2e)-
nitrofurazone [mart.]
nitrofural [iarc]
nitrofurazone [mi]
nitrofurazone [vandf]
hydrazinecarboxamide, 2-((5-nitro-2-furanyl)methylene)
nitrofurazone [orange book]
nitrofurazone [usp-rs]
nitrofurazone [inci]
nitrofurazone [usp monograph]
nitrofurazone [green book]
nitrofurazone [hsdb]
nitrofural [ep monograph]
nitrofural [who-dd]
S1644
HY-B0226
SCHEMBL25416
SCHEMBL25417
tox21_110997_1
NCGC00090686-11
IAIWVQXQOWNYOU-FPYGCLRLSA-N
semioxamazide, 1-(5-nitrofurfurylidene)-
1-(5-nitrofurfurylidene)semicarbazide
component of furadex (salt/mix)
2-((5-nitro-2-furanyl)methylene)hydrazinecarboxamide
nfz mix
component of furea (salt/mix)
Q-201480
chebi:44368 ,
(e)-2-((5-nitrofuran-2-yl)methylene)hydrazine-1-carboxamide
AB00373885_06
AB00373885_05
mfcd00003225
[(e)-[(5-nitrofuran-2-yl)methylidene]amino]urea
sr-05000002027
SR-05000002027-3
nitrofurazone, united states pharmacopeia (usp) reference standard
SR-05000002027-1
nitrofurazone, pharmaceutical secondary standard; certified reference material
nitrofural, european pharmacopoeia (ep) reference standard
nitrofural for peak identification, european pharmacopoeia (ep) reference standard
SBI-0051458.P003
HMS3713D05
nitrofurazone (nitrofural)
2-((5-nitrofuran-2-yl)methylene)hydrazinecarboxamide
BRD-K79092138-001-06-0
structure of 5-nitro-2-furaldehyde-semicarbazone
BS-42205
{[(5-nitrofuran-2-yl)methylidene]amino}urea
EN300-7476664
EN300-7476636
nitrofural (iarc)
fura-septin soluble dressing
2-((5-nitro-2-furyl)methylene)hydrazinecarboxamide
fura ointment
nitrofurazone ointment
nfz puffer
nitrofurazone (mart.)
api furan-2
vetone nitrofurazone
nitrofural (ep monograph)
fura-zone
nitrofurazone (usp monograph)
nitrofurazone soluble dressing
nitrofurazone (usp-rs)
nitrofurazone dressing
nitrofurazone soluble powder
nfz wound dressing
KBIO1_000778
DIVK1C_000778
SPECTRUM_001005
KBIO2_004053
KBIO3_001575
KBIOGR_000631
KBIO2_001485
KBIOSS_001485
KBIO2_006621
SPECTRUM3_000518
SPBIO_000693
SPECTRUM2_000657
PRESTWICK1_000492
SPBIO_002304
NINDS_000778
PRESTWICK0_000492
SPECTRUM4_000076
HMS2234O16
NCGC00090686-10
AKOS017263235
HMS3374P09
FT-0620705
CHEMBL1603968
HMS3655A15
Q27104529
nitrofural;nfz
5-nitrofurfurolsemicarbazon

Research Excerpts

Toxicity

nitrofurazone (0.05%) was uniformly toxic to both cultured human cells and microorganisms. The toxic effects of NFZ on protozoans can be an early warning signal ofNFZ contamination in the aquatic environment.

ExcerptReferenceRelevance
" In the 14-day studies, in which doses ranged from 630 to 10,000 ppm, nitrofurazone was more toxic to mice than to rats."( Toxicity and carcinogenicity of nitrofurazone in F344/N rats and B6C3F1 mice.
Eustis, SL; Haseman, JK; Huff, JE; Kari, FW; Leininger, J, 1989
)
0.28
"05%) was uniformly toxic to both cultured human cells and microorganisms; (2) nitrofurazone (0."( Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts.
Boyce, ST; Holder, IA; Warden, GD,
)
0.13
"To study the 3, 4- dinitro-furazan-based oxidation furazan (DNTF) of sub-acute toxicity and chronic toxicity, to determine the acute toxicity classification DNTF, the nature of toxic effects and major target organ for the development provide the basis for occupational exposure limits."( [3, 4- dinitro-furazan-based oxidation furazan acute and subchronic toxicity studies].
Du, WX; Sun, YH; Wang, YL; Xie, F; Xing, YF; Zhang, YW, 2013
)
0.39
"( 1) Acute oral toxicity test results indicate that DNTF rat oral LD50 greater than 5000 mg/kg, DNTF mice treated by oral LD50 4589 mg/kg, 95%confidence limit for the 4026-5230 mg/kg, Acute toxicity grade level is low toxicity compounds."( [3, 4- dinitro-furazan-based oxidation furazan acute and subchronic toxicity studies].
Du, WX; Sun, YH; Wang, YL; Xie, F; Xing, YF; Zhang, YW, 2013
)
0.39
"With several observable responses and sensitivity of protozoans to nitrofurazone (NFZ), the toxic effects of NFZ on protozoans can be an early warning signal of NFZ contamination in the aquatic environment."( An approach to determining the nitrofurazone-induced toxic dynamics for ecotoxicity assessment using protozoan periphytons in marine ecosystems.
Kazmi, SSUH; Xu, H; Xuexi, T, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" However, the knowledge of pharmacokinetic profile is crucial to evaluate the feasibility of a new drug."( Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits.
Campos, ML; Chin, CM; Davanço, MG; Nogueira Filho, MA; Padilha, EC; Peccinini, RG; Pestana, KC; Pontes Machado, DV, 2013
)
0.39
"4) and in human plasma and to determine preclinical pharmacokinetic parameters in rats."( Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment.
Chung, MC; Ferreira, EI; Moreno, Ade H; Peccinini, RG; Ribeiro, ML; Serafim, EO; Silva, AT; Vizioli, Ede O, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
"Pilot in vitro studies demonstrated that nystatin combined with Silvadene (silver sulfadiazine 1% [Marion Laboratories, Inc."( The efficacy of nystatin combined with topical microbial agents in the treatment of burn wound sepsis.
Desai, MH; Heggers, JP; Herndon, DN; Robson, MC,
)
0.13
"The effect of a collagenous preparation Colocyl and its combination with proteolytic enzymes on the healing of soft tissue purulent wounds were studied in 239 patients."( [Treatment of suppurative wounds of soft tissues with colocyl and its combination with proteolytic enzymes].
Aboiants, RK; Berchenko, GN; Berchenko, VV; Kharitonov, IuK, 1986
)
0.27
" The defects were filled randomly with autogenous bone or the bone substitute materials Algipore and Biogran each combined with a defined quantity of autogenous bone."( [Osseous defect regeneration using autogenous bone alone or combined with Biogran or Algipore with and without added thrombocytes. A microradiologic evaluation].
Kloss, FR; Neukam, FW; Schlegel, KA; Schultze-Mosgau, S; Wiltfang, J, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
" administration, the oral bioavailability of NF from the administered prodrug was obtained (60."( Pharmacokinetics of hydroxymethylnitrofurazone and its parent drug nitrofurazone in rabbits.
Campos, ML; Chin, CM; Davanço, MG; Nogueira Filho, MA; Padilha, EC; Peccinini, RG; Pestana, KC; Pontes Machado, DV, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A single oral dosage of furaltadone and nitrofurazone (14.5 mg) was tested for the effect on two antioxidant enzymes, superoxide dismutase (SOD) and glutathione peroxidase (GPx) in the ciliated protozoan Euplotes vannus. Radioactive residues in milk collected from the dosed quarter were 150 ppb (nitrofurAZone equivalents) and were 39 ppb in milk collection from the undosed quarters at 12 h after dosing.

ExcerptRelevanceReference
" Then we dosed rats orally with these antibiotics and isolated the intensely yellow, polar metabolites from their urine."( Oxidative metabolites of 5-nitrofurans.
Hoener, BA; Krueger, TR; Streeter, AJ, 1988
)
0.27
"A single oral dosage of furaltadone and nitrofurazone (14."( Some pharmacokinetic data about furaltadone and nitrofurazone administered orally to preruminant calves.
Aerts, MM; Degen, M; Driessens, F; Nouws, JF; Vree, TB, 1987
)
0.27
" Incurred NFZ levels exceeded 400 ng drug/g tissue at 2 h after dosing but decreased rapidly to approximately 1 ng drug/g tissue by 8 h after dosing, as determined by this method."( Simultaneous determination of nitrofurazone, nitrofurantoin, and furazolidone in channel catfish (Ictalurus punctatus) muscle tissue by liquid chromatography.
Long, AR; Munns, RK; Plakas, SM; Rupp, HS,
)
0.13
" Copulation and fertility indices were decreased, and pregnancy did not result at doses of 25 mg/kg/day and over with both dosing periods."( Effects of nitrofurazone on spermatogenesis and reproductive toxicity in male rats--part of a collaborative work to determine optimal administration period and endpoints.
Aze, Y; Nishimura, T; Ozeki, Y, 1995
)
0.29
" Radioactive residues in milk collected from the dosed quarter were 150 ppb (nitrofurazone equivalents) and were 39 ppb in milk collected from the undosed quarters at 12 h after dosing."( Distribution of radiocarbon after intramammary, intrauterine, or ocular treatment of lactating cows with carbon-14 nitrofurazone.
Larsen, GL; Paulson, GD; Smith, DJ, 1998
)
0.3
" Chlorohexidine dosage forms Corsodyl and Eludril were used for this purpose."( [The clinico-microbiological evaluation of the efficacy of using new drug forms of chlorhexidine--Corsodyl and Eludril--for the prevention of infectious complications in operations for endosseous implantation].
Biziaev, AF; Chuvilkin, VI; Ivanov, SIu; Kuznetsov, EA; Romanenko, NV; Tsarev, VN, 2000
)
0.31
" At the highest dosage used, the drug was lethal to some of the mice."( The effect of nitrofurazone on Trypanosoma rhodesiense infections in mice.
BAKER, JR, 1959
)
0.24
" The proposed method was validated in terms of accuracy, precision and specificity, and it was successfully applied for the assay of the three nitrofurans in their different dosage forms."( A simple and sensitive spectrofluorimetric method for analysis of some nitrofuran drugs in pharmaceutical preparations.
Belal, TS, 2008
)
0.35
" Hypochlorite dosed into milk on an industrial scale, at concentrations extreme for unintentional residues, produced monochloramine, but, without pH adjustment, hypochlorite alone did not generate semicarbazide."( Semicarbazide is non-specific as a marker metabolite to reveal nitrofurazone abuse as it can form under Hofmann conditions.
Bendall, JG, 2009
)
0.35
" The depletion of cyano metabolite was examined in the muscle of channel catfish after oral dosing (10 mg of NFZ/kg of body weight)."( Cyano metabolite as a biomarker of nitrofurazone in channel catfish.
Abraham, A; El Said, KR; Hooe-Rollman, J; Jester, EL; Plakas, SM; Wang, Y, 2010
)
0.36
" The validated HPLC method was successfully extended to the analysis of the combined topical dosage form (soluble dressing) where no interfering peaks were encountered from the dosage form matrix or the inactive ingredients."( HPLC-DAD stability indicating determination of nitrofurazone and lidocaine hydrochloride in their combined topical dosage form.
Belal, TS; Shaalan, RA, 2010
)
0.36
" In particular, dose-responses for catalase activity and mRNA expression abundance were investigated in Euplotes vannus which were exposed to graded doses of nitrofurazone for several discrete durations, and dose-response models were developed to characterize the dose-response dynamics."( Characterizing dose-responses of catalase to nitrofurazone exposure in model ciliated protozoan Euplotes vannus for ecotoxicity assessment: enzyme activity and mRNA expression.
Al-Rasheid, KA; Li, J; Lin, X; Yi, Z; Zhou, L, 2014
)
0.4
"The equivocality of dose-response relationships has, in practice, hampered the application of biomarkers as a means to evaluate environmental risk, yet this important issue has not yet been fully recognized or explored."( Recognizing the importance of exposure-dose-response dynamics for ecotoxicity assessment: nitrofurazone-induced antioxidase activity and mRNA expression in model protozoan Euplotes vannus.
Al-Rasheid, KA; Hong, Y; Li, J; Lin, X; Liu, S; Yi, Z, 2015
)
0.42
" Potential dose-response models were examined for the effect of nitrofurazone on two antioxidant enzymes, superoxide dismutase (SOD) and glutathione peroxidase (GPx), in the ciliated protozoan Euplotes vannus."( Evaluation of biomarkers for ecotoxicity assessment by dose-response dynamic models: Effects of nitrofurazone on antioxidant enzymes in the model ciliated protozoan Euplotes vannus.
Hong, Y; Li, J; Lin, X; Meng, Y; Tan, Y; Warren, A; Yang, H; Zhang, Y, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
semicarbazoneA hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-acylated nitrogen of semicarbazide or its substituted derivatives.
nitrofuran antibioticA member of the class of furans in which the furan ring is substituted by a nitro group and which also has significant antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (83)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
acetylcholinesteraseHomo sapiens (human)Potency68.40690.002541.796015,848.9004AID1347395; AID1347397; AID1347399
thioredoxin reductaseRattus norvegicus (Norway rat)Potency7.07950.100020.879379.4328AID588453
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency1.09623.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.38600.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency13.32090.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency23.90030.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency30.62010.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency44.66840.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency68.58960.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency39.84400.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency47.94780.000417.946075.1148AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.04980.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency36.97230.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency12.04400.003041.611522,387.1992AID1159552; AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency12.51040.000817.505159.3239AID1159527; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.52540.001530.607315,848.9004AID1224820; AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency68.57030.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency15.04150.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency38.73030.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588513; AID743069; AID743075; AID743079; AID743080
GVesicular stomatitis virusPotency44.78530.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency11.29250.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency54.94100.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency30.89560.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.02450.023723.228263.5986AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency19.33120.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency61.13060.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.82070.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency1.096219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency61.64480.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency18.85410.316212.443531.6228AID902; AID924
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00250.010039.53711,122.0200AID588547
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency7.07950.794321.275750.1187AID624246
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency44.95810.000323.4451159.6830AID743065; AID743066; AID743067
heat shock protein beta-1Homo sapiens (human)Potency54.94100.042027.378961.6448AID743210
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.51660.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency11.22020.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency20.89550.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency3.45560.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency10.18150.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency15.84890.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency25.11890.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency0.01120.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency54.48270.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency44.78530.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency44.78530.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency0.48560.002319.595674.0614AID651631
Integrin beta-3Homo sapiens (human)Potency12.58930.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency12.58930.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency54.48270.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency42.16320.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency44.78530.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency44.78530.01238.964839.8107AID1645842
EWS/FLI fusion proteinHomo sapiens (human)Potency32.77520.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)IC50 (µMol)88.10000.00000.52627.9700AID683161
Snake venom metalloproteinase BaP1Bothrops asper (terciopelo)IC50 (µMol)88.10001.20001.20001.2000AID683161
NAD(+) hydrolase SARM1Homo sapiens (human)IC50 (µMol)90.00003.20004.90008.7000AID1724008
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (256)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
signal transductionNAD(+) hydrolase SARM1Homo sapiens (human)
nervous system developmentNAD(+) hydrolase SARM1Homo sapiens (human)
response to glucoseNAD(+) hydrolase SARM1Homo sapiens (human)
NAD catabolic processNAD(+) hydrolase SARM1Homo sapiens (human)
cell differentiationNAD(+) hydrolase SARM1Homo sapiens (human)
negative regulation of MyD88-independent toll-like receptor signaling pathwayNAD(+) hydrolase SARM1Homo sapiens (human)
regulation of neuron apoptotic processNAD(+) hydrolase SARM1Homo sapiens (human)
innate immune responseNAD(+) hydrolase SARM1Homo sapiens (human)
response to axon injuryNAD(+) hydrolase SARM1Homo sapiens (human)
regulation of dendrite morphogenesisNAD(+) hydrolase SARM1Homo sapiens (human)
nervous system processNAD(+) hydrolase SARM1Homo sapiens (human)
protein localization to mitochondrionNAD(+) hydrolase SARM1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
NAD+ nucleosidase activityNAD(+) hydrolase SARM1Homo sapiens (human)
protein bindingNAD(+) hydrolase SARM1Homo sapiens (human)
signaling adaptor activityNAD(+) hydrolase SARM1Homo sapiens (human)
NADP+ nucleosidase activityNAD(+) hydrolase SARM1Homo sapiens (human)
NAD+ nucleotidase, cyclic ADP-ribose generatingNAD(+) hydrolase SARM1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (63)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmNAD(+) hydrolase SARM1Homo sapiens (human)
mitochondrionNAD(+) hydrolase SARM1Homo sapiens (human)
mitochondrial outer membraneNAD(+) hydrolase SARM1Homo sapiens (human)
cytosolNAD(+) hydrolase SARM1Homo sapiens (human)
microtubuleNAD(+) hydrolase SARM1Homo sapiens (human)
cell surfaceNAD(+) hydrolase SARM1Homo sapiens (human)
axonNAD(+) hydrolase SARM1Homo sapiens (human)
dendriteNAD(+) hydrolase SARM1Homo sapiens (human)
synapseNAD(+) hydrolase SARM1Homo sapiens (human)
protein-containing complexNAD(+) hydrolase SARM1Homo sapiens (human)
dendriteNAD(+) hydrolase SARM1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (198)

Assay IDTitleYearJournalArticle
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1314008Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 measured after 18 hrs by agar dilution method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID386827Antimicrobial activity against Bacillus subtilis after 16 to 18 hrs by serial dilution method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Convenient access to 1,3,4-trisubstituted pyrazoles carrying 5-nitrothiophene moiety via 1,3-dipolar cycloaddition of sydnones with acetylenic ketones and their antimicrobial evaluation.
AID715661Prodrug conversion in Tris-HCl buffer assessed as Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID224393Concentration that cause cytotoxicity at 3.1 uM concentration in mice2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID1149001Antibacterial activity against nitrofuran reductase-deficient Escherichia coli Br 207 after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID1510725Antibacterial activity against Bacillus subtilis2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID466910Antimicrobial activity against Bacillus subtilis after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, characterization and biological activity of some new 1,3,4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety.
AID100905In vitro percent inhibition against mouse peritoneal macrophages infected with Leishmania infantum at 6.2 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID468460Antibacterial activity against Bacillus subtilis after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, characterization and biological activities of some new benzo[b]thiophene derivatives.
AID715476Prodrug conversion in Tris-HCl buffer using NADPH as cofactor assessed as Escherichia coli NfsB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID466912Antimicrobial activity against Pseudomonas aeruginosa after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, characterization and biological activity of some new 1,3,4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety.
AID554821Drug activation in metronidazole-resistant Helicobacter pylori HER 126 V4 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID1510724Antibacterial activity against Staphylococcus aureus2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID432211Antibacterial activity against Bacillus subtilis after 16 to 18 hrs by serial dilution method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Regioselective reaction: synthesis, characterization and pharmacological studies of some new Mannich bases derived from 1,2,4-triazoles.
AID1149002Antibacterial activity against Staphylococcus aureus after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID1724009Noncompetitive inhibition of recombinant human SARM1 TIR domain (561 to 724 residues) expressed in Escherichia coli C43 (DE3) cells lysates assessed as EADPR formation using ENAD as substrate preincubated for 20 mins followed by ENAD addition and measured2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Identification of the first noncompetitive SARM1 inhibitors.
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1149005Antibacterial activity against Proteus rettgeri after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID548284Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID353003Wound healing activity in Wistar albino rat dorsal back excision wound model assessed as epithelization period applied topically as cream base ointment over 100/500mm'2 scar2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity.
AID224389Concentration that cause cytotoxicity at 12.5 uM concentration in mice2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID432213Antibacterial activity against Pseudomonas aeruginosa after 16 to 18 hrs by serial dilution method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Regioselective reaction: synthesis, characterization and pharmacological studies of some new Mannich bases derived from 1,2,4-triazoles.
AID353035Wound healing activity in Wistar albino rat dorsal back excision wound model assessed as wound closure applied topically as 1 %W/W gel base ointment measured after 16 days2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity.
AID23442Partition coefficient (logP)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID466911Antimicrobial activity against Escherichia coli after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, characterization and biological activity of some new 1,3,4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety.
AID576946Toxicity in Swiss mouse infected with Trypanosoma cruzi Tulahuen assessed as occurrence of inactivity at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 2 weeks post dose2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID554819Drug activation in metronidazole-resistant Helicobacter pylori RIG 117 J56 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID214144In vitro percent inhibition against mouse peritoneal macrophages infected with Trypanosoma cruzi at 6.2 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID1149000Antibacterial activity against Escherichia coli Br after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID470198Antibacterial activity against Staphylococcus aureus after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, characterization and biological activities of some new benzo[b]thiophene derivatives.
AID224395Concentration that cause cytotoxicity at 6.2 uM concentration in mice2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID396116Antibacterial activity against Bacillus subtilis by serial dilution method2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Synthesis and antimicrobial activities of a new series of 4-S-[4(1)-amino-5(1)-oxo-6(1)-substituted benzyl-4(1),5(1)-dihydro-1(1),2(1),4(1)-triazin-3-yl]mercaptoacetyl-3-arylsydnones.
AID548280Antimicrobial activity against Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1724008Inhibition of recombinant human SARM1 TIR domain (561 to 724 residues) expressed in Escherichia coli C43 (DE3) cells lysates using ENAD as substrate preincubated for 20 mins followed by ENAD addition and measured at 15 sec interval for 15 mins2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Identification of the first noncompetitive SARM1 inhibitors.
AID715475Prodrug conversion in Tris-HCl buffer using NADH as cofactor assessed as Escherichia coli NfsB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID386824Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 16 to 18 hrs by serial dilution method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Convenient access to 1,3,4-trisubstituted pyrazoles carrying 5-nitrothiophene moiety via 1,3-dipolar cycloaddition of sydnones with acetylenic ketones and their antimicrobial evaluation.
AID554816Drug activation in metronidazole-susceptible Helicobacter pylori CAS 015 J0 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID396115Antibacterial activity against Escherichia coli ATCC 25922 by serial dilution method2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Synthesis and antimicrobial activities of a new series of 4-S-[4(1)-amino-5(1)-oxo-6(1)-substituted benzyl-4(1),5(1)-dihydro-1(1),2(1),4(1)-triazin-3-yl]mercaptoacetyl-3-arylsydnones.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID715473Ratio of apparent Kcat to apparent Km for Escherichia coli NfsB-mediated prodrug conversion using NADH as cofactor by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID554820Drug activation in metronidazole-resistant Helicobacter pylori CAS 015 J56 lysate harboring rdxA L132stop and frxA L39stop mutant genes2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID1149003Antibacterial activity against Streptococcus faecalis after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID554817Drug activation in metronidazole-susceptible Helicobacter pylori HER 126 V1 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID576943Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as parasite DNA level at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 180 days post dose 2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID215701In vitro percent inhibition against mouse peritoneal macrophages infected with Trypanosoma brucei at 1.5 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID1274542Antibacterial activity against gram-positive Staphylococcus epidermidis ATCC 12228 at 5 mg/ml incubated overnight by agar well diffusion method2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols.
AID1323834Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by scintillation proximity assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID1510727Antibacterial activity against Pseudomonas aeruginosa2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID683161Inhibition of snake venom BaP1 using Abz-Ala-Gly-Leu-Ala-Nba as substrate incubated for 30 mins prior to substrate addition by fluorescence spectrophotometry2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Identification of new snake venom metalloproteinase inhibitors using compound screening and rational Peptide design.
AID396114Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by serial dilution method2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Synthesis and antimicrobial activities of a new series of 4-S-[4(1)-amino-5(1)-oxo-6(1)-substituted benzyl-4(1),5(1)-dihydro-1(1),2(1),4(1)-triazin-3-yl]mercaptoacetyl-3-arylsydnones.
AID1323835Displacement of [3H]rosiglitazone from recombinant human C-terminal His-tagged MitoNEET cytosolic domain (32 to 108 residues) expressed in Escherichia coli BL21 by Cheng-Prusoff analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of small molecules that bind to the mitochondrial protein mitoNEET.
AID27580Partition coefficient (logP)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1149007Antibacterial activity against Klebsiella pneumoniae after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID577158Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in reduction in parasite induced histopathological changes in skeletal muscle at 150 mg/kg/day, po for 6 days per week until completion of 60 compound 2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID318681Anticarcinogenic activity in rat assessed as induction of tumors per day2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
AID1149006Antibacterial activity against Pseudomonas aeruginosa after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID353032Wound healing activity in Wistar albino rat dorsal back excision wound model assessed as wound closure applied topically as 1 %W/W gel base ointment measured after 4 days2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity.
AID1274541Antibacterial activity against gram-positive Staphylococcus aureus ATCC 3591 at 5 mg/ml incubated overnight by agar well diffusion method2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols.
AID576950Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in parasite specific antibodies at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measu2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1053268Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID577159Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in reduction in parasite induced histopathological changes in liver at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses admi2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID386826Antimicrobial activity against sPseudomonas aeruginosa ATCC 27853 after 16 to 18 hrs by serial dilution method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Convenient access to 1,3,4-trisubstituted pyrazoles carrying 5-nitrothiophene moiety via 1,3-dipolar cycloaddition of sydnones with acetylenic ketones and their antimicrobial evaluation.
AID215682Effective concentration in vitro against the bloodstream trypomastigote form of Trypanosoma brucei; ND means not determined2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID554818Drug activation in metronidazole-resistant Helicobacter pylori 10593a/2 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID554814Drug activation in metronidazole-susceptible Helicobacter pylori 10593/2 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID434354Wound healing activity in po dosed Swiss albino rat incision wound model assessed as skin breaking strength after 10 days2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Evaluation of in vivo wound-healing potential of 2-[4-(2,4-dimethoxy-benzoyl)-phenoxy]-1-[4-(3-piperidin-4-yl-propyl)-piperidin-1-yl]-ethanone derivatives.
AID466909Antimicrobial activity against Staphylococcus aureus after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis, characterization and biological activity of some new 1,3,4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety.
AID577161Toxicity in Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as changes in liver SGOT enzyme levels at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection by hematoxylin-eosin staining2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID353033Wound healing activity in Wistar albino rat dorsal back excision wound model assessed as wound closure applied topically as 1 %W/W gel base ointment measured after 8 days2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity.
AID19427HPLC capacity factor (k)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID1314009Antibacterial activity against Staphylococcus saprophyticus ATCC 15305 measured after 18 hrs by broth dilution method2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Modification of existing antibiotics in the form of precursor prodrugs that can be subsequently activated by nitroreductases of the target pathogen.
AID548283Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID470196Antibacterial activity against Escherichia coli after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, characterization and biological activities of some new benzo[b]thiophene derivatives.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID548282Antimicrobial activity against Trypanosoma brucei NfxR22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID386825Antimicrobial activity against sEscherichia coli ATCC 25922 after 16 to 18 hrs by serial dilution method2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Convenient access to 1,3,4-trisubstituted pyrazoles carrying 5-nitrothiophene moiety via 1,3-dipolar cycloaddition of sydnones with acetylenic ketones and their antimicrobial evaluation.
AID1149004Antibacterial activity against Proteus mirabilis after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID1274539Antibacterial activity against gram-negative Escherichia coli ATCC 11229 at 5 mg/ml incubated overnight by agar well diffusion method2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols.
AID576944Toxicity in Swiss mouse infected with Trypanosoma cruzi Tulahuen assessed as occurrence of erected hair at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 2 weeks post dose2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID715477Ratio of apparent Kcat to apparent Km for Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated reduction by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID576941Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as parasite DNA level at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 30 days post dose b2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID548281Antimicrobial activity against Trypanosoma brucei NfxR12010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID353004Wound healing activity in Wistar albino rat dorsal back incision wound model assessed as tensile strength applied topically as cream base ointment over 100/500 mm'2 scar by tensiometry2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity.
AID396113Antibacterial activity against Staphylococcus aureus ATCC 25923 by serial dilution method2008European journal of medicinal chemistry, Dec, Volume: 43, Issue:12
Synthesis and antimicrobial activities of a new series of 4-S-[4(1)-amino-5(1)-oxo-6(1)-substituted benzyl-4(1),5(1)-dihydro-1(1),2(1),4(1)-triazin-3-yl]mercaptoacetyl-3-arylsydnones.
AID215850In vitro percent inhibition against mouse peritoneal macrophages infected with Trypanosoma brucei at 3.1 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID576948Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as reduction in blood parasite load at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID1274540Antibacterial activity against gram-negative Pseudomonas aeruginosa ATCC 2785 at 5 mg/ml incubated overnight by agar well diffusion method2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and evaluation of antibacterial and antitumor activities of new galactopyranosylated amino alcohols.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID470197Antibacterial activity against Pseudomonas aeruginosa after 16 to 18 hrs by serial dilution method2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis, characterization and biological activities of some new benzo[b]thiophene derivatives.
AID576938Antimicrobial activity against Trypanosoma cruzi Tulahuen infected in Swiss mouse assessed as mouse mortality rate at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID715665Prodrug conversion in Tris-HCl buffer assessed as Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB-mediated hydroxylamine derivative formation after 30 mins by HPLC analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1724007Inhibition of recombinant human SARM1 TIR domain (561 to 724 residues) expressed in Escherichia coli C43 (DE3) cells lysates using ENAD as substrate at 25 uM preincubated for 20 mins followed by ENAD addition and measured after 1 hr relative to control2020Bioorganic & medicinal chemistry, 09-15, Volume: 28, Issue:18
Identification of the first noncompetitive SARM1 inhibitors.
AID576945Toxicity in Swiss mouse infected with Trypanosoma cruzi Tulahuen assessed as occurrence of dehydration at 150 mg/kg/day, po for 6 days per week until completion of 60 compound doses administered 5 days post infection measured 2 weeks post dose2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease.
AID554815Drug activation in metronidazole-susceptible Helicobacter pylori RIG 117 J0 lysate2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
A redox basis for metronidazole resistance in Helicobacter pylori.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID432210Antibacterial activity against Staphylococcus aureus after 16 to 18 hrs by serial dilution method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Regioselective reaction: synthesis, characterization and pharmacological studies of some new Mannich bases derived from 1,2,4-triazoles.
AID224391Concentration that cause cytotoxicity at 25 uM concentration in mice2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID1510728Antifungal activity against Candida albicans2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID200690Mutagenic activity in an Ames test on Salmonella Typhimurium TA98; Activity is log of revertants/nmol1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity.
AID1148999Antibacterial activity against Escherichia coli B after 6 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID29421Partition coefficient (logP) (HPLC)2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
ElogPoct: a tool for lipophilicity determination in drug discovery.
AID214141In vitro percent inhibition against mouse peritoneal macrophages infected with Trypanosoma cruzi at 25 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID215851In vitro percent inhibition against mouse peritoneal macrophages infected with Trypanosoma brucei at 6.2 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID715463Ratio of apparent Kcat/apparent Km for Escherichia coli NfsB to apparent Kcat/apparent Km for Staphylococcus saprophyticus ATCC 15305 Ssap-NtrB2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID715474Ratio of apparent Kcat to apparent Km for Escherichia coli NfsB-mediated prodrug conversion using NADPH as cofactor by steady state kinetics analysis2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
An unusually cold active nitroreductase for prodrug activations.
AID1053269Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID353034Wound healing activity in Wistar albino rat dorsal back excision wound model assessed as wound closure applied topically as 1 %W/W gel base ointment measured after 12 days2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of novel benzo[h]quinolines: wound healing, antibacterial, DNA binding and in vitro antioxidant activity.
AID100902In vitro percent inhibition against mouse peritoneal macrophages infected with Leishmania infantum at 25 uM concentration2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID215514Minimum effective concentration in vitro against the bloodstream trypomastigote form of Trypanosoma brucei2003Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3
Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead.
AID1149010Antibacterial activity against Escherichia coli Br cultured in Penassay broth assessed as effect on lag time after 9 hrs by turbidimetric analysis1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Chemistry and antibacterial activity of nitrobenzofurans.
AID432212Antibacterial activity against Escherichia coli after 16 to 18 hrs by serial dilution method2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Regioselective reaction: synthesis, characterization and pharmacological studies of some new Mannich bases derived from 1,2,4-triazoles.
AID1510726Antibacterial activity against Escherichia coli2019European journal of medicinal chemistry, Oct-01, Volume: 179Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (893)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990602 (67.41)18.7374
1990's54 (6.05)18.2507
2000's90 (10.08)29.6817
2010's105 (11.76)24.3611
2020's42 (4.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.67 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index100.81 (26.88)
Search Engine Supply Index2.55 (0.95)

This Compound (52.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (2.70%)5.53%
Trials0 (0.00%)5.53%
Reviews27 (2.70%)6.00%
Reviews0 (0.00%)6.00%
Case Studies45 (4.50%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other901 (90.10%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Efficacy and Safety of Nitrazine in the Treatment of Amyotrophic Lateral Sclerosis: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study [NCT04950647]Phase 2150 participants (Anticipated)Interventional2020-07-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]